Spectrum Pharmaceuticals Shares Outstanding 2006-2018 | SPPI

Spectrum Pharmaceuticals shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Spectrum Pharmaceuticals shares outstanding for the quarter ending June 30, 2018 were 0.113B, a 43.32% increase year-over-year.
  • Spectrum Pharmaceuticals 2017 shares outstanding were 0.085B, a 16.88% increase from 2016.
  • Spectrum Pharmaceuticals 2016 shares outstanding were 0.073B, a 12.24% increase from 2015.
  • Spectrum Pharmaceuticals 2015 shares outstanding were 0.065B, a 0.27% increase from 2014.
Spectrum Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2017 85
2016 73
2015 65
2014 65
2013 61
2012 65
2011 58
2010 50
2009 39
2008 32
2007 29
2006 24
2005 18
Spectrum Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
Q2 2018 113
Q1 2018 101
Q4 2017 85
Q3 2017 83
Q2 2017 79
Q1 2017 79
Q4 2016 73
Q3 2016 79
Q2 2016 69
Q1 2016 66
Q4 2015 65
Q3 2015 66
Q2 2015 65
Q1 2015 65
Q4 2014 65
Q3 2014 65
Q2 2014 65
Q1 2014 63
Q4 2013 61
Q3 2013 62
Q2 2013 59
Q1 2013 59
Q4 2012 65
Q3 2012 65
Q2 2012 63
Q1 2012 65
Q4 2011 58
Q3 2011 59
Q2 2011 58
Q1 2011 56
Q4 2010 50
Q3 2010 50
Q2 2010 49
Q1 2010 49
Q4 2009 39
Q3 2009 44
Q2 2009 34
Q1 2009 32
Q4 2008 32
Q3 2008 32
Q2 2008 32
Q1 2008 31
Q4 2007 29
Q3 2007 31
Q2 2007 28
Q1 2007 25
Q4 2006 24
Q3 2006 24
Q2 2006 24
Q1 2006 24
Q4 2005 18
Q3 2005 17
Q2 2005 15
Q1 2005 15
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $2.263B $0.128B
Spectrum Pharmaceuticals, Inc. is opportunistically acquiring and advancing a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum's expertise lies in identifying undervalued drugs with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most viable and low-risk methods of commercialization. The company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease.
Stock Name Country Market Cap PE Ratio
Shire (SHPG) Ireland $54.219B 11.49
Zoetis (ZTS) United States $43.282B 31.41
Grifols (GRFS) Spain $14.428B 18.70
Tilray (TLRY) United States $11.457B 0.00
Neurocrine Biosciences (NBIX) United States $10.822B 0.00
Nektar Therapeutics (NKTR) United States $10.176B 11.90
Jazz Pharmaceuticals (JAZZ) Ireland $9.894B 14.56
Impax Laboratories (AMRX) United States $7.032B 0.00
Sage Therapeutics (SAGE) United States $6.813B 0.00
Ionis Pharmaceuticals (IONS) United States $6.746B 0.00
Catalent (CTLT) United States $6.179B 26.66
United Therapeutics (UTHR) United States $5.347B 6.86
FibroGen (FGEN) United States $4.874B 0.00
Loxo Oncology (LOXO) United States $4.853B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.920B 15.18
Endo (ENDP) Ireland $3.610B 5.18
Madrigal Pharmaceuticals (MDGL) United States $3.248B 0.00
USANA Health Sciences (USNA) United States $2.892B 25.48
Aerie Pharmaceuticals (AERI) United States $2.643B 0.00
Ironwood Pharmaceuticals (IRWD) United States $2.630B 0.00
Heron Therapeutics (HRTX) United States $2.441B 0.00
Xencor (XNCR) United States $2.394B 0.00
PTC Therapeutics (PTCT) United States $2.269B 0.00
TESARO (TSRO) United States $2.070B 0.00
Pacira Pharmaceuticals (PCRX) United States $2.069B 0.00
Portola Pharmaceuticals (PTLA) United States $1.821B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.791B 21.90
Zogenix (ZGNX) United States $1.761B 0.00
Corcept Therapeutics (CORT) United States $1.665B 25.63
Theravance Biopharma (TBPH) Cayman Islands $1.600B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $1.564B 0.00
Tricida (TCDA) United States $1.534B 0.00
TherapeuticsMD (TXMD) United States $1.532B 0.00
ImmunoGen (IMGN) United States $1.350B 0.00
Endocyte (ECYT) United States $1.233B 0.00
Esperion Therapeutics (ESPR) United States $1.157B 0.00
Karyopharm Therapeutics (KPTI) United States $1.110B 0.00
Radius Health (RDUS) United States $0.815B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.796B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.749B 0.00
Flexion Therapeutics (FLXN) United States $0.697B 0.00
Dova Pharmaceuticals (DOVA) United States $0.675B 0.00
ChemoCentryx (CCXI) United States $0.635B 37.97
GlycoMimetics (GLYC) United States $0.611B 0.00
Siga Technologies (SIGA) United States $0.572B 0.00
Odonate Therapeutics (ODT) United States $0.565B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.562B 0.00
OptiNose (OPTN) United States $0.559B 0.00
ArQule (ARQL) United States $0.553B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.539B 0.00
Collegium Pharmaceutical (COLL) United States $0.508B 0.00
CASI Pharmaceuticals (CASI) United States $0.494B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.474B 0.00
Akebia Therapeutics (AKBA) United States $0.472B 0.00
Minerva Neurosciences (NERV) United States $0.471B 0.00
Aclaris Therapeutics (ACRS) United States $0.470B 0.00
Majesco Entertainment (PTE) United States $0.465B 0.00
Translate Bio (TBIO) United States $0.451B 0.00
Dermira (DERM) United States $0.434B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.427B 29.11
Verrica Pharmaceuticals (VRCA) United States $0.419B 0.00
Synergy Pharmaceuticals (SGYP) United States $0.419B 0.00
Xeris Pharmaceuticals (XERS) United States $0.418B 0.00
Forty Seven (FTSV) United States $0.411B 0.00
Aquestive Therapeutics (AQST) United States $0.407B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.398B 0.00
Zafgen (ZFGN) United States $0.397B 0.00
Mast Therapeutics (SVRA) United States $0.393B 0.00
Depomed (ASRT) United States $0.392B 0.00
ElectroCore (ECOR) United States $0.392B 0.00
KalVista Pharmaceuticals (KALV) United States $0.373B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.356B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.345B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.323B 0.00
Concert Pharmaceuticals (CNCE) United States $0.317B 0.00
MEI Pharma (MEIP) United States $0.313B 0.00
Opexa Therapeutics (ACER) United States $0.301B 0.00
Aratana Therapeutics (PETX) United States $0.284B 0.00
Affimed (AFMD) Germany $0.273B 0.00
Galectin Therapeutics (GALT) United States $0.267B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.265B 0.00
Ardelyx (ARDX) United States $0.258B 0.00
Melinta Therapeutics (MLNT) United States $0.252B 0.00
Ocular Therapeutix (OCUL) United States $0.249B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.244B 0.00
Tyme Technologies (TYME) United States $0.242B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.239B 0.00
IMV INC (IMV) Canada $0.232B 0.00
Jounce Therapeutics (JNCE) United States $0.220B 0.00
Neon Therapeutics (NTGN) United States $0.215B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.204B 0.00
Lannett Co Inc (LCI) United States $0.195B 1.61
Aldeyra Therapeutics (ALDX) United States $0.191B 0.00
Achaogen (AKAO) United States $0.190B 0.00
Calithera Biosciences (CALA) United States $0.178B 0.00
DURECT (DRRX) United States $0.173B 0.00
MediWound (MDWD) Israel $0.172B 0.00
Redhill Biopharma (RDHL) Israel $0.171B 0.00
Nature's Sunshine Products (NATR) United States $0.169B 0.00
Immune Design (IMDZ) United States $0.169B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.161B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.154B 0.00
Adherex Technologies (FENC) United States $0.154B 0.00
Molecular Templates (MTEM) United States $0.149B 0.00
Neos Therapeutics (NEOS) United States $0.148B 0.00
Champions Oncology (CSBR) United States $0.148B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.147B 0.00
Recro Pharma (REPH) United States $0.146B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.145B 0.00
Cardiome Pharma (CORV) Canada $0.140B 0.00
ProNAi Therapeutics (SRRA) Canada $0.138B 0.00
Infinity Pharmaceuticals (INFI) United States $0.136B 0.00
ContraFect (CFRX) United States $0.129B 0.00
CTI BioPharma (CTIC) United States $0.115B 0.00
Forward Pharma (FWP) Denmark $0.112B 0.00
Iterum Therapeutics (ITRM) Ireland $0.105B 0.00
BioLineRx (BLRX) Israel $0.104B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.089B 0.00
Trillium Therapeutics (TRIL) Canada $0.087B 0.00
Nivalis Therapeutics (ALPN) United States $0.086B 0.00
Otonomy (OTIC) United States $0.083B 0.00
Natural Alternatives (NAII) United States $0.077B 8.69
KemPharm (KMPH) United States $0.072B 0.00
Novan (NOVN) United States $0.070B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.062B 0.00
SCYNEXIS (SCYX) United States $0.059B 0.00
Mannatechorporated (MTEX) United States $0.049B 25.57
Genocea Biosciences (GNCA) United States $0.048B 0.00
Tokai Pharmaceuticals (NVUS) United States $0.047B 0.00
Capnia (SLNO) United States $0.046B 0.00
Heat Biologics (HTBX) United States $0.045B 0.00
Onconova Therapeutics (ONTX) United States $0.042B 0.00
Avenue Therapeutics (ATXI) United States $0.036B 0.00
ProPhase Labs (PRPH) United States $0.035B 0.00
PharmAthene (ALT) United States $0.034B 0.00
Lipocine (LPCN) United States $0.033B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.033B 0.00
Jaguar Animal Health (JAGX) United States $0.032B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.032B 0.00
Biomerica (BMRA) United States $0.031B 0.00
Xenetic Biosciences (XBIO) United States $0.031B 0.00
Citius Pharmaceuticals (CTXR) United States $0.029B 0.00
HANCOCK JAFFE (HJLI) United States $0.028B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.027B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.024B 0.00
Midatech Pharma (MTP) United Kingdom $0.024B 0.00
Aviragen Therapeutics (VXRT) United States $0.023B 0.00
Regulus Therapeutics (RGLS) United States $0.022B 0.00
Shineco (TYHT) China $0.022B 1.85
Cyanotech (CYAN) United States $0.020B 0.00
Aradigm (ARDM) United States $0.018B 0.00
DelMar Pharmaceuticals (DMPI) Canada $0.018B 0.00
CollPlant Holdings Sponsored ADR (CLGN) Israel $0.017B 0.00
ESSA Pharma (EPIX) Canada $0.015B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.015B 0.00
Skyline Medical (AIPT) United States $0.014B 0.00
Intellipharmaceutics (IPCI) Canada $0.013B 0.00
OncoGenex Pharmaceuticals (ACHV) United States $0.011B 0.00
Ohr Pharmaceuticals (OHRP) United States $0.011B 0.00
Ritter Pharmaceuticals (RTTR) United States $0.010B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.010B 0.00
Bio-Path Holdings (BPTH) United States $0.007B 0.00
Apricus Biosciences (APRI) United States $0.007B 0.00
Pain Therapeutics (PTIE) United States $0.007B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.006B 0.00
RXi Pharmaceuticals (RXII) United States $0.005B 0.00
Bio Blast Pharma (ORPN) Israel $0.004B 0.00
Auris Medical Holding AG (EARS) Switzerland $0.002B 0.00
Advanced Accelerator Applications (AAAP) France $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00